VRTX

Vertex Pharmaceuticals Inc / Ma

A global biotech developing transformative medicines for serious diseases, Vertex Pharmaceuticals is best known for its cystic fibrosis franchise — KALYDECO, ORKAMBI, SYMDEKO, TRIKAFTA, and ALYFTREK — which treats most people with CF in key Western markets. The company also makes CASGEVY, a CRISPR gene-editing therapy for sickle cell disease and beta thalassemia, and JOURNAVX, a non-opioid pain signal inhibitor for acute pain. Its pipeline targets kidney disease, chronic pain, and type 1 diabetes.

Recent Activity

Show $

2026Q2

5 sells

ARK Genomic Revolution ETFEXIT

-25.9K shares

ARK Genomic Revolution ETFEXIT

-25.9K shares

Bridgewater Associates LPTRIM

-2.5K shares(-18.7%)

Bridgewater Associates LPTRIM

-2.5K shares(-18.7%)

Torray Investment PartnersTRIM

-171 shares(-1.1%)

Torray Investment PartnersTRIM

-171 shares(-1.1%)

Tweedy, Browne CompanyTRIM

-266 shares(-0.7%)

Tweedy, Browne CompanyTRIM

-266 shares(-0.7%)

Tweedy, Browne Value FundTRIM

-700 shares(-4.9%)

Tweedy, Browne Value FundTRIM

-700 shares(-4.9%)

2026Q1

1 buy4 sells

ARK Genomic Revolution ETFTRIM

-155 shares(-0.6%)

ARK Genomic Revolution ETFTRIM

-155 shares(-0.6%)

ARK InvestEXIT

-26.1K shares

ARK InvestEXIT

-26.1K shares

Bridgewater Associates LPTRIM

-14.1K shares(-51.4%)

Bridgewater Associates LPTRIM

-14.1K shares(-51.4%)

Torray Investment PartnersTRIM

-80 shares(-0.5%)

Torray Investment PartnersTRIM

-80 shares(-0.5%)

Tweedy, Browne CompanyADD

+1.2K shares(+3.2%)

Tweedy, Browne CompanyADD

+1.2K shares(+3.2%)

Loading more activity...